Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) shares were down 3.2% on Monday . The company traded as low as $75.32 and last traded at $75.88, with a volume of 510,356 shares changing hands. The stock had previously closed at $78.42.

A number of research analysts have recently weighed in on ALNY shares. Jefferies Group restated a “buy” rating and issued a $122.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, April 19th. FBR & Co restated an “outperform” rating and issued a $180.00 target price on shares of Alnylam Pharmaceuticals in a report on Sunday, July 17th. Zacks Investment Research lowered Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 25th. Needham & Company LLC restated a “buy” rating and issued a $152.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, July 1st. Finally, Morgan Stanley started coverage on Alnylam Pharmaceuticals in a report on Tuesday, August 2nd. They issued an “overweight” rating and a $93.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $116.42.

The stock’s 50 day moving average is $63.54 and its 200 day moving average is $63.43. The stock’s market cap is $6.53 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.24) by $0.19. The firm had revenue of $8.70 million for the quarter, compared to analysts’ expectations of $8.09 million. During the same quarter last year, the company posted ($0.85) EPS. The firm’s revenue was up .2% on a year-over-year basis. Equities research analysts predict that Alnylam Pharmaceuticals Inc. will post ($4.78) EPS for the current year.

In other Alnylam Pharmaceuticals news, CEO John Maraganore sold 30,151 shares of the company’s stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $64.69, for a total transaction of $1,950,468.19. Following the transaction, the chief executive officer now owns 148,465 shares in the company, valued at approximately $9,604,200.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Several hedge funds recently bought and sold shares of ALNY. Mutual of America Capital Management LLC increased its stake in Alnylam Pharmaceuticals by 0.4% in the fourth quarter. Mutual of America Capital Management LLC now owns 21,637 shares of the biopharmaceutical company’s stock valued at $2,037,000 after buying an additional 87 shares during the last quarter. Gulf International Bank UK Ltd increased its stake in Alnylam Pharmaceuticals by 1.0% in the fourth quarter. Gulf International Bank UK Ltd now owns 23,100 shares of the biopharmaceutical company’s stock valued at $2,175,000 after buying an additional 220 shares during the last quarter. Advisors Asset Management Inc. increased its stake in Alnylam Pharmaceuticals by 0.3% in the fourth quarter. Advisors Asset Management Inc. now owns 64,827 shares of the biopharmaceutical company’s stock valued at $6,103,000 after buying an additional 226 shares during the last quarter. Jennison Associates LLC increased its stake in Alnylam Pharmaceuticals by 0.5% in the fourth quarter. Jennison Associates LLC now owns 1,489,541 shares of the biopharmaceutical company’s stock valued at $140,225,000 after buying an additional 7,296 shares during the last quarter. Finally, BlackRock Advisors LLC increased its stake in Alnylam Pharmaceuticals by 8.2% in the fourth quarter. BlackRock Advisors LLC now owns 179,529 shares of the biopharmaceutical company’s stock valued at $16,901,000 after buying an additional 13,612 shares during the last quarter.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.